The FDA approves Merck KGaA and Pfizer’s Bavencio as first-line maintenance therapy in bladder cancer

Merck KGaA and Pfizer’s Bavencio, a PD-L1 class drug, has recently been given FDA approval as first-line maintenance therapy in bladder cancer, following its already established use in bladder cancer patients whose condition has progressed following chemo.

The approval was based on the back data, announced at the American Society of Clinical Oncology’s online yearly meeting, highlighting that Bavencio could reduce a patient’s risk of fatality by thirty-one per cent, in comparison with best supportive care. Furthermore, patients who received the medicine survived for a median of twenty-one-point-four months, compared with fourteen-point-three months on standard therapy.

The partners are expecting to see immediate uptake from doctors due to the approval being one of the most substantial progress in the treatment paradigm in this context in three decades.